BR112012010325A2 - comprimida com liberação sustentada contendo teobromina - Google Patents
comprimida com liberação sustentada contendo teobrominaInfo
- Publication number
- BR112012010325A2 BR112012010325A2 BR112012010325A BR112012010325A BR112012010325A2 BR 112012010325 A2 BR112012010325 A2 BR 112012010325A2 BR 112012010325 A BR112012010325 A BR 112012010325A BR 112012010325 A BR112012010325 A BR 112012010325A BR 112012010325 A2 BR112012010325 A2 BR 112012010325A2
- Authority
- BR
- Brazil
- Prior art keywords
- sustained release
- release layer
- weight
- release tablet
- theobromine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
comprimido com liberação sustentada contendo teobromina. a presnete invenção refere-se a um comprimido com liberação sustentada que contém teobromina. mais especificamente, a presente invenção refere-se a um comprimido com liberação sustentada que contém teobrimina, o qual compreende uma camada d eliberação sustentada e uma camada de liberação imediata, sendo que a camada de liberação sustentada e uma camada de liberação imediata, sendo que a camada de liberação sustentada possui de 40% a 60% em pseo d eteobromina como ingrediente ativo e de 14% e 19% em peso de uma base de liberação sustentada composta por óxido de polietileno e hidroxipropilmetilcelulose, ao passo que a camada de liberação imediata possui d e10% a 30% em peso de teobromina como ingrediente ativo e de 0,5% a 2% em peso de um desagregante composto por um ou mais elementos escolhidos dentre croscarmelose sódica, crospovidona e glicolato d emaido sódico. o comprimido de liberação sustentada da presente invenção melhora efetivamente vários tipos de sintomas da tosse, bastando tomá-lo uma vez ao dia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2009-0105137 | 2009-11-02 | ||
| KR1020090105137A KR101137467B1 (ko) | 2009-11-02 | 2009-11-02 | 테오브로민 함유 서방성 정제 |
| PCT/KR2010/005911 WO2011052884A2 (ko) | 2009-11-02 | 2010-09-01 | 테오브로민 함유 서방성 정제 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012010325A2 true BR112012010325A2 (pt) | 2016-03-29 |
| BR112012010325B1 BR112012010325B1 (pt) | 2021-01-26 |
| BR112012010325B8 BR112012010325B8 (pt) | 2021-05-25 |
Family
ID=43922740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012010325A BR112012010325B8 (pt) | 2009-11-02 | 2010-09-01 | comprimido com liberação sustentada e imediata de teobromina |
Country Status (7)
| Country | Link |
|---|---|
| KR (1) | KR101137467B1 (pt) |
| CN (1) | CN102711740B (pt) |
| BR (1) | BR112012010325B8 (pt) |
| RU (1) | RU2506947C2 (pt) |
| TR (1) | TR201205029T1 (pt) |
| UA (1) | UA103558C2 (pt) |
| WO (1) | WO2011052884A2 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101220830B1 (ko) * | 2010-08-18 | 2013-01-10 | 안국약품 주식회사 | 테오브로민의 서방성 과립제 및 그 제조방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR040680A1 (es) * | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Composicion de tabletas de liberacion sostenida |
| DE10353196A1 (de) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| KR20070017335A (ko) * | 2004-03-22 | 2007-02-09 | 노파르티스 아게 | 리카르바제핀을 포함하는 경구투여용 매트릭스 제제 |
| CN101111231A (zh) * | 2005-03-29 | 2008-01-23 | 罗姆有限公司 | 包含具有影响调节物质递送的基质的小丸的多颗粒药用形式 |
| KR100762847B1 (ko) * | 2006-01-27 | 2007-10-04 | 씨제이 주식회사 | 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법 |
-
2009
- 2009-11-02 KR KR1020090105137A patent/KR101137467B1/ko active IP Right Grant
-
2010
- 2010-09-01 WO PCT/KR2010/005911 patent/WO2011052884A2/ko active Application Filing
- 2010-09-01 TR TR2012/05029T patent/TR201205029T1/xx unknown
- 2010-09-01 RU RU2012119070/15A patent/RU2506947C2/ru active
- 2010-09-01 CN CN201080051266.9A patent/CN102711740B/zh not_active Expired - Fee Related
- 2010-09-01 UA UAA201206606A patent/UA103558C2/ru unknown
- 2010-09-01 BR BR112012010325A patent/BR112012010325B8/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TR201205029T1 (tr) | 2012-09-21 |
| CN102711740B (zh) | 2014-02-12 |
| RU2506947C2 (ru) | 2014-02-20 |
| WO2011052884A3 (ko) | 2011-07-14 |
| CN102711740A (zh) | 2012-10-03 |
| RU2012119070A (ru) | 2013-12-10 |
| BR112012010325B8 (pt) | 2021-05-25 |
| UA103558C2 (ru) | 2013-10-25 |
| BR112012010325B1 (pt) | 2021-01-26 |
| KR20110048367A (ko) | 2011-05-11 |
| KR101137467B1 (ko) | 2012-04-20 |
| WO2011052884A2 (ko) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19078196A (es) | Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
| CY1122330T1 (el) | Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης | |
| CY1117728T1 (el) | Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλ) κυκλοπροπανοκαρβοξαμιδο)-3-μεθυλπυριδιν-2-υλ)βενζοϊκου οξεος | |
| AR052925A1 (es) | Forma cristalina betad del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| CY1110097T1 (el) | Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων | |
| UY30578A1 (es) | Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones | |
| BRPI0820856A2 (pt) | anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos | |
| AR069031A1 (es) | Composicion | |
| EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
| MX2012007375A (es) | 3-ceto-n-propargil 1-aminoindano. | |
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| ECSP099320A (es) | Compuestos de tetrahidropirrolopiracina sustituida y su aplicación en medicamentos | |
| FR2949062B1 (fr) | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments | |
| NI201200168A (es) | Formulaciones farmacéuticas | |
| EA201071204A1 (ru) | Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности | |
| RU2014143536A (ru) | Фармацевтическая композиция, содержащая омелсартана медоксомил и розувастатин или его соль | |
| BRPI0806713A8 (pt) | Composições de tiacumicinas estáveis | |
| NI201100227A (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica. | |
| TR201010683A1 (tr) | Vildagliptin formülasyonları. | |
| ECSP099561A (es) | Formulación de nevirapina de liberación prolongada | |
| CO6321223A2 (es) | Formulacion farmaceutica solida que contiene ciclostazol | |
| DK1994926T3 (da) | Valsartanformuleringer | |
| UY33723A (es) | ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?. | |
| BR112014020184A8 (pt) | Preparação farmacêutica que contém anlodipina e ra-mipril | |
| PE20142460A1 (es) | Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/01/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/09/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2738 DE 27-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |